Windtree Therapeutics Long-Term Debt 2011-2026 | WINT

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Windtree Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
653 K	1.16 M	1.62 M	2.07 M	2.42 M	19.6 M	15 M	15 M	25 M	25 M	20.3 M	18.4 M	100 K	200 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
25 M	100 K	10.5 M

Quarterly Long-Term Debt Windtree Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
240 K	381 K	519 K	653 K	784 K	912 K	1.04 M	1.16 M	1.25 M	1.4 M	1.51 M	1.62 M	1.73 M	1.84 M	1.94 M	2.07 M	2.2 M	2.32 M	2.44 M	201 K	201 K	201 K	201 K	794 K	794 K	794 K	794 K	-	-	-	-	-	12.5 M	12.5 M	12.5 M	25 M	25 M	25 M	25 M	25 M	25 M	25 M	25 M	20.3 M	20.3 M	20.3 M	20.3 M	18.4 M	18.4 M	18.4 M	18.4 M	-	-	-	-	224 K	224 K	224 K	224 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
25 M	201 K	8.46 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Grifols, S.A. GRFS	5.9 B	$ 8.24	-0.12 %	$ 6.83 B	Spain
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	173 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
AbbVie ABBV	64.5 B	$ 208.84	-2.86 %	$ 369 B	USA
AbCellera Biologics ABCL	137 M	$ 3.52	0.28 %	$ 1.05 B	Canada
Acorda Therapeutics ACOR	167 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	86 M	-	-	$ 86.2 M	USA
Advaxis ADXS	8.14 M	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	49 K	-	-	$ 10.1 M	USA
Aeterna Zentaris AEZS	31 K	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	2.95 M	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	2.29 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	30.5 M	$ 3.33	-2.06 %	$ 99 M	USA
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	9.12 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
Allena Pharmaceuticals ALNA	210 K	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	3.38 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	69 K	-	10.36 %	$ 9.8 M	USA
Adaptive Biotechnologies Corporation ADPT	127 M	$ 14.81	2.63 %	$ 2.25 B	USA
Altimmune ALT	34.3 M	$ 3.34	7.05 %	$ 294 M	USA
BioNTech SE BNTX	231 M	$ 91.18	1.97 %	$ 27.2 B	Germany
Amgen AMGN	50 B	$ 347.94	-1.51 %	$ 187 B	USA
ANI Pharmaceuticals ANIP	309 M	$ 74.21	-2.3 %	$ 1.43 B	USA
Aravive ARAV	1.88 M	-	-13.39 %	$ 1.45 M	USA
Arcturus Therapeutics Holdings ARCT	20.8 M	$ 8.03	2.29 %	$ 220 M	Israel
Aptose Biosciences APTO	193 K	-	-45.71 %	$ 1.2 M	Canada
Aurinia Pharmaceuticals AUPH	52.3 M	$ 15.61	0.9 %	$ 2.1 B	Canada
Autolus Therapeutics plc AUTL	66.8 M	$ 1.41	2.17 %	$ 375 M	Britain
Aptinyx APTX	22.1 M	-	-39.0 %	$ 4.57 M	USA
Aytu BioScience AYTU	10.9 M	$ 2.68	1.52 %	$ 16.8 M	USA
CureVac N.V. CVAC	25.4 M	-	-	$ 867 M	Germany
AstraZeneca PLC AZN	17.5 B	-	-	$ 96.9 B	Britain
Avenue Therapeutics ATXI	2.03 M	-	-52.27 %	$ 4.45 M	USA
Atea Pharmaceuticals AVIR	842 K	$ 5.76	1.95 %	$ 469 M	USA
AVROBIO AVRO	188 K	-	1083.1 %	$ 745 M	USA
BioCryst Pharmaceuticals BCRX	315 M	$ 9.02	-3.84 %	$ 1.86 B	USA
Axcella Health AXLA	25.1 M	-	-16.42 %	$ 249 M	USA
Axon Enterprise AXON	41.4 M	$ 412.81	-2.54 %	$ 31.3 B	USA
Alnylam Pharmaceuticals ALNY	1.01 B	$ 318.85	-3.01 %	$ 41.8 B	USA
Ayala Pharmaceuticals AYLA	1.33 M	-	-	$ 7.46 M	Israel